Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Relmada Therapeutics Inc
RLMD | US
7.21
USD-0.04
-0.55%
RLMD | US
Loading StockChartView...
About Relmada Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
24/04/2026
Close
7.21
Open
7.26
High
7.27
Low
6.98
Relmada Therapeutics Inc. a clinical-stage biotechnology company focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone dextromethadone and REL-1017) a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables Florida.
View LessRLMD | US
Risk
65.6
Sharpe
6.77
Luna's Score
52/100
Recommendation
Hold
Luna says (RLMD | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
49.6%1 month
65.6%3 months
141.3%6 months
122.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.71
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.54
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-161.25M
MarketCap
217.56M
MarketCap(USD)
217.56M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-100.41
Short ratio
3.86
Short perc.
4.22
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.13
Range1M
1.75
Range3M
4.72
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.49
Price X volume
4.92M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.54 | 24.85 | Cheaper |
| Ent. to Revenue | - | 361.91 | - |
| PE Ratio | - | 30.05 | - |
| Price to Book | 1.71 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 141.31 | 65.24 | Riskier |
| Debt to Equity | - | -1.88 | - |
| Debt to Assets | - | 0.48 | - |
| Market Cap | 217.56M | 3.71B | Emerging |
